A Phase I Toxicity and Feasibility Trial of Sequential Dose-Dense Induction Chemotherapy with Doxorubicin, Paclitaxel, and 5-Fluorouracil Followed by High Dose Consolidation for High-Risk Primary Breast Cancer

Author： Emens L.A.   Kennedy M.J.   Fetting J.H.   Davidson N.E.   Garrett E.   Armstrong D.K.  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.76, Iss.2, 2002-11, pp. : 145-156

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adjuvant Dose-Dense Sequential Chemotherapy with Epirubicin, CMF and Weekly Paclitaxel in Patients with Resected High-Risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study

By Papadimitriou Christos   Papakostas Pavlos   Timotheadou Eleni   Aravantinos Gerasimos   Bamias Aristotelis   Fountzilas George  

Cancer Investigation, Vol. 26, Iss. 5, 2008-06 ,pp. : 491-498

Informa Healthcare

Access to resources Recommend Favorite

Paclitaxel-containing High-dose Chemotherapy in High-risk Breast Cancer Patients

By Greinix Hildegard T.   Linkesch Werner   Seifert Manfred   Kubista Ernst   Czerwenka Klaus   Elahi Fariborz   Zielinski Christoph   Hoecker Paul   Steger Günther   Schulenburg Axel   Neumeister Geralt   Rabitsch Werner   Jakesz Raimund   Kalhs Peter  

Acta Oncologica, Vol. 39, Iss. 1, 2000-04 ,pp. : 47-52

Informa Healthcare

Access to resources Recommend Favorite

Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: A phase II study

By Kümmel Sherko   Thomas Anke   Paepke Stefan   Schwarz Marion   Heinrich Georg   Wetzel Andrea   Elling Dirk   Kohls Andreas   Lichtenegger Werner   Blohmer Jens-Uwe  

Acta Oncologica, Vol. 44, Iss. 3, 2005-05 ,pp. : 248-254

Informa Healthcare

Access to resources Recommend Favorite

Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer

By Cooper Brenda   Radivoyevitch Tomas   Overmoyer Beth   Shenk Robert   Pham Huong   Samuels Judith   Parry Margaret   Silverman Paula  

Breast Cancer Research and Treatment, Vol. 97, Iss. 3, 2006-06 ,pp. : 311-318

Springer Publishing Company

Access to resources Recommend Favorite

Acute and Late Toxicity Following Adjuvant High-Dose Chemotherapy for High-Risk Primary Operable Breast Cancer A Quality Assessment Study

By Svane Inge M.   Homburg Keld M.   Kamby Claus   Nielsen Dorte L.   Roer Ole   Sliffsgaard Dorte   Johnsen Hans E.   Hansen Steen W.  

Acta Oncologica, Vol. 41, Iss. 7-8, 2002-11 ,pp. : 675-683

Informa Healthcare

Access to resources Recommend Favorite